Anal Fistula Treatment Market By Product/Treatment Type (Surgical and Procedural Treatments, Fistula Closure Devices and Biomaterials, Biologics, Stem Cell and Regenerative Therapies); By Application (Cryptoglandular Anal Fistulas, Crohn’s-Associated Perianal Fistulas, Other Anal Fistulas); By End User (Hospitals, Ambulatory Surgical Centres, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Anal Fistula Treatment Market: Procedure-Led Demand, Recurring Crohn’s Care and Evidence-Driven Innovation

The Global Anal Fistula Treatment Market was valued at USD 790 million in 2025 and is projected to reach USD 1.08 billion by 2032, expanding at a CAGR of 4.6% during 2026–2032, according to Strategic Market Research.

 

Anal fistula treatment remains largely dominated by surgical and minimally invasive procedures, while biologic and stem-cell therapies are becoming increasingly important in the approved and clinical pipeline landscape. These regenerative approaches focus mainly on promoting local tissue repair, controlling inflammation through immunomodulation, improving healing outcomes, and reducing recurrence while preserving surrounding tissue.

 

Rare Prevalence Still Creates a Persistent Treatment Pipeline

European evidence estimated anal fistula prevalence at 1.69 cases per 10,000 people and annual incidence at approximately 1.15 per 10,000. Cryptoglandular disease represented 50.8% of prevalent cases, Crohn’s-associated disease accounted for 44.6%, and other causes made up the remaining 4.6%. Among incident cases, cryptoglandular fistulas held a larger 74.9% patient share, supported by an estimated incidence of 0.86 per 10,000. These figures describe the clinical population mix rather than revenue distribution, but they show why the market combines a broad procedure-led segment with a smaller recurring-therapy segment.

Although the total patient pool is relatively small, treatment intensity is meaningful. Patients may move through abscess drainage, imaging, examination under anaesthesia, seton placement, closure procedures, follow-up and revision treatment. Crohn’s-associated patients may also receive induction, maintenance, switching or combination pharmaceutical therapy. Commercial demand is therefore tied less to prevalence alone and more to the number of clinical events generated across each treatment pathway.

Anorectal abscesses form an important upstream referral pool. A Catalonian population study followed 27,821 adults treated for a first anorectal abscess between 2018 and 2022 and found that approximately 20% subsequently developed a clinically detected fistula. This progression share means that roughly one in five abscess patients entered a subsequent fistula-care pathway. For hospitals and treatment suppliers, the conversion creates demand for follow-up consultations, imaging, surgical planning and procedure-linked products.

 

Surgical Procedures Form the Broadest Revenue Base

Surgery reaches the widest group of patients because it is relevant to most cryptoglandular fistulas and remains part of care for many Crohn’s-associated cases. Treatment selection depends on anatomy, sphincter involvement, infection, previous procedures and recurrence. Fistulotomy remains the main treatment for many simple fistulas, while setons, advancement flaps, ligation of the intersphincteric fistula tract, plugs and endoscopic techniques address patients for whom cutting through sphincter muscle would create an unacceptable continence risk.

Direct national evidence from England and Wales demonstrates the depth of this procedural pathway. A  UK Hospital Episode Statistics study analysed 36,223 patients who underwent an anal fistula operation across 148 NHS trusts. Around 67.4% had only one operation during the recorded follow-up, while the remaining 32.6% underwent more than one operation. The median interval between the first and second procedures was 27.4 weeks.

The 67.4% single-procedure share supports the market’s core volume base, while the 32.6% repeat-procedure share creates additional revenue through operating-room time, surgeon services, anaesthesia, setons, closure materials, dressings and follow-up care. Repeat demand also raises the commercial value of products that improve healing durability, reduce recurrence or protect continence. Hospitals are less likely to accept higher-priced products when the added cost does not produce a measurable improvement in outcomes or treatment efficiency.

 

Complex Anatomy Moves Spending Toward Sphincter-Preserving Options

Conventional fistulotomy remains effective for many simple fistulas and therefore limits the premium-device opportunity in lower-complexity cases. Higher-value spending is concentrated in complex, transsphincteric, recurrent or branching fistulas where continence preservation shapes treatment choice. These patients support demand for specialist imaging, endoscopic systems, bioabsorbable implants, collagen-based products and trained-user support.

Video-assisted anal fistula treatment illustrates the capital-and-consumable revenue model within the market. NICE reported a 2017 price of £7,988 for the reusable VAAFT surgical kit and approximately £20 in single-use consumables per procedure. The pricing structure shows how suppliers can earn revenue through capital acquisition, accessories, sterilisation, servicing and clinician training. It also separates the segment from conventional procedures that rely mainly on lower-cost operating-room consumables.

Provider evidence indicates that VAAFT remains in use in specialist NHS care for difficult or complex fistulas. Continued symptoms or incomplete healing can still require additional treatment, keeping procurement decisions closely tied to long-term outcomes. Karl Storz participates in this segment through its VAAFT fistuloscopy platform and associated instruments. The system targets complex and recurrent cases rather than the larger simple-fistula population, making specialist-centre penetration, training relationships, service support and procedure throughput central to commercial success.

 

Bioabsorbable Implants Create a New US Device Category

The US Food and Drug Administration granted De Novo classification to Signum Surgical’s BioHealx Anal Fistula Device on 1 July 2024, establishing a Class II regulatory category for anal fistula closure devices. The approved indication covers mature, cryptogenic, transsphincteric, non-branching fistulas and does not include Crohn’s-associated disease. This positions the device within a narrow but clinically difficult patient segment rather than the full surgical market.

The FDA decision summary reported complete healing in 19 of 32 patients, equal to a 59.4% healing share by the final visit. Three patients, or 9.4%, experienced recurrence, while ten patients, representing 31.2%, were downgraded from transsphincteric fistulas to sinus or superficial fistulas that could require secondary treatment. All participants had previously undergone at least one unsuccessful treatment.

The De Novo decision gives Signum Surgical and future competitors a clearer regulatory route for differentiated closure devices. Adoption will depend on post-market results, surgeon training, reimbursement, distributor access and evidence that the implant can reduce repeat operations or protect continence sufficiently to justify its added cost. The 59.4% complete-healing result supports commercial interest, while the combined 40.6% recurrence-or-downgrade share keeps evidence generation central to broader adoption.

Cook Biotech already participates in the biologic-plug category through the FDA-cleared Biodesign Anal Fistula Plug. Its 2019 clearance confirms an established hospital purchasing category for implantable fistula-repair materials. Competition between plugs, bioabsorbable closure implants and conventional procedures will centre on anatomical eligibility, healing durability, recurrence, handling, safety and total treatment cost.

 

Crohn’s-Associated Fistulas Support Recurring Drug Revenue

The pharmaceutical portion of the market is concentrated in active perianal fistulising Crohn’s disease. Crohn’s-associated fistulas represented 44.6% of prevalent European anal fistula cases in the available epidemiological evidence, compared with a smaller share of incident cases. Their longer duration and recurrence create recurring treatment value that is not captured by annual new-patient counts alone.

A US claims study covering 2017–2019 estimated fistulising Crohn’s disease prevalence at 24.9 per 100,000 people and incidence at 7.0 per 100,000 person-years. Approximately half of incident patients received a biologic within one year of fistula diagnosis, with anti-tumour necrosis factor therapy representing the most widely prescribed biologic class. Around one-third underwent surgery during follow-up, demonstrating that the pharmaceutical and surgical pathways continue to overlap within this patient group.

Infliximab holds the strongest established guideline position in this subgroup. The American Gastroenterological Association recommends infliximab for induction and maintenance of fistula remission in adult outpatients with active perianal Crohn’s fistulas. The commercial profile differs from surgery because treatment continues through induction and maintenance, creating recurring pharmacy or infusion revenue rather than a single procedure episode.

Medical therapy remains closely connected to surgery. Clinical guidance supports drainage and seton control of sepsis before medical or closure therapy in appropriate patients, followed by anti-TNF treatment and surgical closure where suitable. Perianal Crohn’s care therefore requires coordination among gastroenterologists, colorectal surgeons, radiologists, specialist nurses, pharmacies and payers.

This combined-care pathway favours companies with established inflammatory bowel disease access, reimbursement support and specialist-prescriber relationships. It also creates demand for switching and combination treatment because complete and durable closure is not achieved in every patient. The drug pathway is narrower than the full surgical population but offers recurring revenue, longer patient engagement and greater sensitivity to formulary access.

 

Cell Therapy Withdrawal Raises the Evidence Bar

Darvadstrocel, marketed as Alofisel, represented a premium cell-therapy approach for complex perianal fistulas in adults with non-active or mildly active Crohn’s disease. Its initial European approval was supported by the 212-patient ADMIRE-CD study, which produced a 15.8-percentage-point difference over placebo at 24 weeks. The European marketing authorisation was withdrawn in December 2024 after the 568-patient ADMIRE-CD II confirmatory trial failed to meet its primary endpoint and showed no statistically significant differences across secondary endpoints.

The withdrawal increases the evidence threshold for future regenerative therapies. Early approval and specialist positioning are not enough to sustain market access when confirmatory benefit is not reproduced. Future cell therapies and gene-modified products will need larger controlled trials, consistent closure definitions, imaging-supported evidence, long-term recurrence data and a clear advantage over combined anti-TNF and surgical care.

Clinical investigation of darvadstrocel has continued in Crohn’s-associated complex perianal fistulas, keeping regenerative treatment within the development landscape. Commercial value will depend on trial design, target population, regulatory progress and comparative performance rather than the number of pipeline assets.

 

Outpatient Care Expands Access and Tightens Pricing

Many anal fistula operations can be delivered without an overnight stay, making hospital outpatient departments and selected ambulatory surgery centres important purchasing channels. Same-day care supports demand for products that fit shorter procedural workflows, but it also increases pressure on procedure time, disposable cost and follow-up burden.

The broader US ambulatory infrastructure included 6,436 Medicare-certified ASCs that performed 6.4 million procedures for 3.4 million fee-for-service beneficiaries in 2024. Medicare payments and beneficiary cost sharing for ASC services reached approximately USD 7.5 billion. Only a portion of these facilities support colorectal fistula care, but the scale of the channel creates a route for eligible procedures that meet safety, coverage and facility requirements.

MedPAC reported that ASC payment rates averaged 44% below hospital outpatient prospective payment-system rates. This payment gap rewards products that can reduce recurrence, avoid continence complications, shorten treatment pathways or enable suitable patients to be managed outside higher-cost inpatient settings. Devices that add unit cost without producing a clear clinical or economic benefit will face stronger purchasing resistance.

 

Regional Opportunity Reflects Data Quality and Provider Access

Europe provides the strongest published epidemiological foundation, with cross-country prevalence and incidence estimates and a prevalent-case mix led by cryptoglandular disease at 50.8%, followed by Crohn’s-associated disease at 44.6%. The United Kingdom adds direct evidence on diagnosed prevalence, national operating activity, provider participation and repeat surgery. The combination of 36,223 operated patients, 148 NHS trusts and a 32.6% repeat-operation share makes the UK particularly useful for modelling procedure demand and provider distribution.

Spain contributes a defined upstream patient funnel through the Catalonian abscess cohort. The finding that approximately 20% of abscess patients later developed a fistula connects emergency treatment with subsequent colorectal demand and supports structured follow-up pathways.

The United States offers strong regulatory and outpatient-infrastructure signals. The BioHealx De Novo decision created a defined implant category, while Medicare data show a large ambulatory purchasing base. US growth potential is concentrated in specialist device adoption, outpatient procedure migration and recurring Crohn’s therapy, with commercial performance shaped by reimbursement, claims visibility and provider capability.

 

Competitive Advantage Will Depend on Outcomes and Pathway Fit

The competitive landscape includes specialist implant developers such as Signum Surgical, biologic-material suppliers such as Cook Biotech, capital-equipment companies such as Karl Storz, established colorectal-device suppliers and pharmaceutical companies serving Crohn’s disease. These companies compete across patient groups divided by fistula cause, anatomy, sphincter involvement, treatment history, Crohn’s activity and payer approval.

Standard fistulotomy, seton placement and basic consumables will remain the volume foundation. Premium value is more concentrated in complex and recurrent fistulas, where providers may accept additional cost to preserve continence or reduce further intervention. Biologics retain recurring value in Crohn’s-associated disease, while advanced cell therapies face a substantially higher clinical and reimbursement barrier after the Alofisel withdrawal.

 

Strategic Outlook: Growth Will Come From Better Treatment Conversion

The anal fistula treatment market is projected to expand from USD 790 million in 2025 to USD 1.08 billion by 2032, adding USD 290 million in annual revenue at a 4.6% CAGR. The market has two connected revenue engines: episodic surgical care across the broader patient population and recurring medical therapy within Crohn’s-associated disease. Procedure volume, repeat operations and specialist outpatient care support the current market base, while higher-value expansion is expected from complex-fistula implants, sphincter-preserving platforms, stronger combined-care pathways and therapies that demonstrate durable closure in well-designed trials.

 

Anal Fistula Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 790 Million
Revenue Forecast in 2032	USD 1.08 Billion
Overall Growth Rate	CAGR of 4.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product/Treatment Type, By Application, By End User, By Region
By Product/Treatment Type	Surgical and Procedural Treatments, Fistula Closure Devices and Biomaterials, Biologics, Stem Cell and Regenerative Therapies
By Application	Cryptoglandular Anal Fistulas, Crohn’s-Associated Perianal Fistulas, Other Anal Fistulas
By End User	Hospitals, Ambulatory Surgical Centres, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing prevalence of anal fistula cases, growing adoption of minimally invasive treatment approaches, rising demand for advanced fistula closure technologies and regenerative therapies
Customization Option	Available upon request